July 09, 2025

ESC: Vaccines May Prevent Major Heart Events

A new ESC clinical statement finds that common vaccines, including those for influenza and COVID-19, may lower cardiovascular risks such as heart attack, stroke, and heart failure, particularly in high-risk patients.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 19, 2025

Plaque Calcification May Predict Future Hemorrhage Risk

New research tracked subclinical carotid plaque changes over six years and found that plaques with calcification were twice as likely to develop intraplaque hemorrhage, with men showing greater risk for complex plaque progression.

Conexiant

June 13, 2025

Obicetrapib-Ezetimibe Combo Cuts LDL Nearly 50%

A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.

Conexiant

November 19, 2024

Wide Variation in SGLT2i Use Across U.S. Hospitals

Study reveals hospital variation in SGLT2i prescriptions, with only 11 of 518 hospitals (2.1%) achieving ≥50% prescription rates while 232 hospitals (44.8%) prescribed to fewer than 10% of eligible heart failure patients, highlighting an implementation gap in evidence-based therapy.

Conexiant

January 09, 2025

Study: Aspirin Shields SLE Patients from ASCVD

A recent study has linked antiphospholipid antibodies to atherosclerotic cardiovascular disease in systemic lupus erythematosus patients, highlighting the potential of aspirin to reduce risk. Source: BMC Medicine

Conexiant

April 30, 2025

ApoB Count and Lp(a) Levels Key to CAD Risk

Total apoB particle count and Lp(a) levels best reflect coronary artery disease risk, with researchers noting that lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P.

Conexiant

May 30, 2025

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.

Conexiant